ABC | Volume 114, Nº5, Maio 2020

Artigo de Revisão Askin et al. COVID-19 e doenças cardiovasculares Arq Bras Cardiol. 2020; 114(5):817-822 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 23. BoothCM,MatukasLM,TomlinsonGA,RachlisAR,RoseDB,DwoshHA,etal. Clinicalfeaturesandshort-termoutcomesof144patientswithSARSinthegreater Torontoarea. JAMA.2003;289(21):2801-9. 24. KlimasJ,OlvedyM,Ochodnicka-MackovicovaK,KruzliakP,CacanyiovaS,Kristek F, et al. Perinatally administered losartana augments renal ECA2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. J Cell Mol Med.2015;19(8):1965-74. 25. WaltersTE,KalmanJM,PatelSK,MearnsM,VelkoskaE,BurrellLM.Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensinconvertingenzyme2activity isassociatedwithatrial fibrillationand moreadvancedleftatrialstructuralremodelling.Europace.2017;19(8):1280-7. 26. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin‑converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-6. 27. Kuba K, Imai Y, Rao S, GaoH, Guo F, Guan B, et al. A crucial role of angiotensin convertingenzyme2(ACE2)inSARScoronavírus-inducedlunginjury.NatMed. 2005;11(8):875-9. 28. ClinicalTrials.gov. Losartana for Pacientes With COVID19 Not Requiring Hospitalization. Identifier: NCT04311177; 2020. [citado 17 mar 2020]. Disponívelem: https://clinicaltrials.gov/ct2/show/NCT04311177. 29. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirusdisease2019(COVID-19)andCardiovascularDisease.Circulation. 2020Mar21. [Epubaheadofprint]. 30. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, et al. Clinical characteristicsandoutcomesof112cardiovasculardiseasepatients infectedby 2019-nCoV.ZhonghuaXinXueGuanBingZaZhi.2020Mar2;48(0):E004. 31. Si Y, Sun XF, Zhong M, Yue JN, Fu WG. Countermeasures and treatment for aorticacutesyndromewith2019coronavirusdisease.ZhonghuaWaiKeZaZhi 2020;58(3):178-82. 32. ElfikyAA.Anti-HCV,nucleotide inhibitors,repurposingagainstCOVID-19.Life Sci.2020May1;248:117477. 33. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavirinthetreatmentofSARS:initialvirologicalandclinicalfindings. Thorax.2004;59(3):252-6. 34. Byetta [package insert].SanDiego,CA:AmylinPharmaceuticals Inc;2007. 35. KALETRA(R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution. Product Insert. AbbVie Inc. (per FDA), North Chicago, IL;2013. 36. DeCarolis DD, Westanmo AD, Chen YC, Boese AL, Walquist MA, Rector TS. Evaluation of a potential interaction between new regimens to treat hepatitis C andwarfarin.AnnPharmacother.2016;50(11):909-17. 37. Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, et al. Effect of ketoconazoleanddiltiazemonthepharmacokineticsofapixaban,anoraldirect factorXa inhibitor.Br JClinPharmacol.2015;79(5):838-46. 38. MueckW,KubitzaD,BeckaM.Co-administrationofrivaroxabanwithdrugsthat share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J ClinPharmacol.2013;76(3):455-66. 39. Brilinta(Ticagrelor)-Prescribinginformation.Wilmington,DE:AstraZenecaLP; 2011 40. Brilinta (ticagrelor). Product monograph. Mississauga, Ontario, Canada: AstraZenecaCanada Inc.,:2011. 41. ItkonenMK,TornioA,Lapatto-ReiniluotoO,NeuvonenM,NeuvonenPJ,Niemi M, et al. Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel. Clin Pharmacol Ther. 2019;105(1):219-28. 42. Marsousi N, Daali Y, Fontana P, Reny JL, Ancrenaz-Sirot V, Calmy A, et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin Pharmacokinet. 2018;57(10):1347-54. 43. Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies.Circulation.2017;136(20):1955-75. 44. Kengreal [package insert].Cary,NC:ChiesiUSA, INC;2015. 45. Mulangu S, Dodd LE, Davey RT Jr, Tshiani Mbaya O, Proschan M, Mukadi D, et al. A randomized, controlled trial of ebola virus disease therapeutics. NEngl J Med.2019;381(24):2293-303. 46. WangM,CaoR,ZhangL,YangX,LiuJ,XuM,etal.Remdesivirandchloroquine effectivelyinhibittherecentlyemergednovelcoronavíirus(2019-nCoV)invitro. CellRes.2020;30(3):269-71. 47. GaoJ,TianZ,YangX.Breakthrough:chloroquinephosphatehasshownapparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BiosciTrends.2020;14(1):72-3. 48. Tonnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy - a review ofthe literature. Immunopharmacol Immunotoxicol.2013;35(3):434-42. 49. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Bondi-Zoccai G, et al. Cardiovascular Considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J AmColl Cardiol.2020Mar18:pii:S0735-1097(20)34637-4. 50. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J,et al. Clinical and biochemical indexes from2019-nCoV infected patients linked to viral loads and lung injury. SciChinaLifeSci.2020;63(3):364-74. 51. DiazJH.Hypothesis:angiotensin-convertingenzymeinhibitorsandangiotensin receptorblockersmayincreasetheriskofsevereCOVID-19.JTravelMed.2020 Mar18;pii:taaa041. 52. ChenC,ChenC,YanJT,ZhouN,ZhaoJP,WangDW.Analysisofmyocardialinjury inpatientswithCOVID-19andassociationbetweenconcomitantcardiovascular diseases and severity of COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(0):E008. 53. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. 54. RuanQ, Yang K, WangW, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients fromWuhan, China. IntensiveCareMed.2020Mar3. [Epubaheadofprint]. 55. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020Mar11. [Epubaheadofprint]. 56. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020 May;177:104762. 57. GuanWJ,LiangWH,ZhaoY,LiangHR,ChenZS,LiYM,etal.Comorbidityand its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J.2020Mar26;pii:2000547. 58. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol.2020Mar27. [Epubaheadofprint]. 59. Guo T, Fan Y, ChenM, Wu X, Zhang L, He T, et al. Cardiovascular implications offataloutcomesofpatientswithcoronavirusdisease2019(COVID-19).JAMA Cardiol.2020Mar27. [Epubaheadofprint]. 60. Shi S, QinM, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol.2020Mar25. [Epubaheadofprint]. 61. Chen X, HuW, Ling J, Mo P, Zhang Y, Jiang Q, et al. Hypertension and diabetes delaytheviralclearance inCOVID-19patients.medRxiv.2020Mar24. 62. Tignanelli CJ, IngrahamNE, Sparks MA, Reilkoff R, Bezdicek T, Benson B, et al. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med. 2020 Mar 26. [Epubaheadofprint]. 822